Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Eli Lilly and (NYSE:LLY) with a Outperform ...

The drugmaker Ely Lilly ( LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...

But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...

Dave Ricks of Eli Lilly is having a banner year. All that innovation, of course, is expensive, as we know, because drug company CEOs are often pilloried in the court of public opinion. But take a ...

Essence may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals ... and its stock soar in recent times. It consists of the company's weight loss drugs: Mounjaro, approved for type 2 diabetes but ...

Eli Lilly (LLY) has filed a lawsuit against the heads of the Department of Health and Human Services and one of its agencies, seeking a court ...

The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...

Eli Lilly (NYSE ... still could carve out share. And a company of its size -- with a market value of $6.7 billion compared to the $777 billion of Lilly -- may become highly successful even ...

Eli Lilly dominates today's market for weight loss drugs, with two blockbusters. A smaller company, a biotech player, aims to join this billion-dollar market and recently reported fantastic ...